Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Dyne Therapeutics Inc shares valued at $911,000 were purchased by Cox John on Jul 14 ’25. At $9.11 per share, Cox John acquired 100,000 shares. The insider’s holdings grew to 242,179 shares worth approximately $2.81 million following the completion of this transaction.
Also, Scalzo Richard William purchased 1,330 shares, netting a total of over 19,619 in proceeds.
Before that, Beskrovnaya Oxana had added 2,132 shares to its account. In a trade valued at $31,449, the Officer bought Dyne Therapeutics Inc shares for $14.75 each.
As published in their initiating research note from Bernstein on June 24, 2025, Dyne Therapeutics Inc [DYN] has been a Mkt perform and the price target has been revised to $13. Earlier on May 29, 2025, Evercore ISI initiated its rating. Their recommendation was “an Outperform” for DYN stock.
Analyzing DYN Stock Performance
On last trading session, Dyne Therapeutics Inc [NASDAQ: DYN] rose 10.70% to $11.59. The stock’s lowest price that day was $9.89, but it reached a high of $13.5 in the same session. During the last five days, there has been a surge of approximately 16.95%. Over the course of the year, Dyne Therapeutics Inc shares have dropped approximately -71.61%.
Is Dyne Therapeutics Inc subject to short interest?
Stocks of Dyne Therapeutics Inc saw a sharp steep in short interest on 2025-07-15 dropping by -4.89 million shares to 15.73 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 20.62 million shares. A decline of -31.1% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.13 of the overall float, the days-to-cover ratio (short ratio) decline to 4.13.
Which companies own the most shares of Dyne Therapeutics Inc (DYN)?
In terms of Dyne Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 46 in the next 12 months, up nearly 339.35% from the previous closing price of $10.47. Analysts anticipate Dyne Therapeutics Inc stock to reach 48 by 2025, with the lowest price target being 34. In spite of this, 8 analysts ranked Dyne Therapeutics Inc stock as Buy at the end of 2025. On March 12, 2025, BMO Capital Markets assigned a price target of “an Outperform” to the stock and initiated coverage with a $50.
